IUPAC/Chemical Name
(R)-N-(5-(tert-Butyl)-1H-pyrazol-3-yl)-2-(3-isopropylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
InChi Key
HNOLTAKAPDKZRY-AWEZNQCLSA-N
InChi Code
InChI=1S/C20H30N8/c1-12(2)14-11-28(9-8-21-14)19-24-17-13(6-7-22-17)18(25-19)23-16-10-15(26-27-16)20(3,4)5/h6-7,10,12,14,21H,8-9,11H2,1-5H3,(H3,22,23,24,25,26,27)/t14-/m0/s1
SMILES Code
CC([C@@H]1CN(C2=NC(NC3=NNC(C(C)(C)C)=C3)=C4C(NC=C4)=N2)CCN1)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Spastazoline is a selective spastin inhibitor, with an IC50 of 99 nM for Human spastin.
In vitro activity:
The findings of this study suggest that spastin is critical for spinal cord injury (SCI) recovery and may be a potential target for SCI treatment. Inhibiting spastin with spastazoline significantly suppressed the microtubule-severing activity of spastin in COS-7 cells and inhibited the promoting effect of spastin on neurite outgrowth in primarily cultured hippocampal neurons.
Reference: Brain Res Bull. 2023 Dec;205:110806. https://pubmed.ncbi.nlm.nih.gov/37918696/
In vivo activity:
Spastin is important for successful SCI recovery. Inhibition of spastin with spastazoline reversed the effects of the 14-3-3 agonist FC-A, which promotes axonal regrowth and nerve regeneration in spinal cord injury models. Spastin inhibition leads to negative patient outcomes for SCIs.
Reference: Elife. 2024 Jan 17;12:RP90184. https://pubmed.ncbi.nlm.nih.gov/38231910/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
100.0 |
261.43 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
382.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Yang J, Zhang Y, Cai Z, Zou J, Li S, Miao G, Lin H, Zhao X, Tan M. Inhibition of spastin impairs motor function recovery after spinal cord injury. Brain Res Bull. 2023 Dec;205:110806. doi: 10.1016/j.brainresbull.2023.110806. Epub 2023 Oct 31. PMID: 37918696.
2. Liu Q, Yang H, Luo J, Peng C, Wang K, Zhang G, Lin H, Ji Z. 14-3-3 protein augments the protein stability of phosphorylated spastin and promotes the recovery of spinal cord injury through its agonist intervention. Elife. 2024 Jan 17;12:RP90184. doi: 10.7554/eLife.90184. PMID: 38231910.
In vitro protocol:
1. Yang J, Zhang Y, Cai Z, Zou J, Li S, Miao G, Lin H, Zhao X, Tan M. Inhibition of spastin impairs motor function recovery after spinal cord injury. Brain Res Bull. 2023 Dec;205:110806. doi: 10.1016/j.brainresbull.2023.110806. Epub 2023 Oct 31. PMID: 37918696.
In vivo protocol:
1. Liu Q, Yang H, Luo J, Peng C, Wang K, Zhang G, Lin H, Ji Z. 14-3-3 protein augments the protein stability of phosphorylated spastin and promotes the recovery of spinal cord injury through its agonist intervention. Elife. 2024 Jan 17;12:RP90184. doi: 10.7554/eLife.90184. PMID: 38231910.
1: Cupido T, Pisa R, Kelley ME, Kapoor TM. Designing a chemical inhibitor for the AAA protein spastin using active site mutations. Nat Chem Biol. 2019 May;15(5):444-452. doi: 10.1038/s41589-019-0225-6. Epub 2019 Feb 18. PMID: 30778202; PMCID: PMC6558985.
2: Pisa R, Cupido T, Steinman JB, Jones NH, Kapoor TM. Analyzing Resistance to Design Selective Chemical Inhibitors for AAA Proteins. Cell Chem Biol. 2019 Sep 19;26(9):1263-1273.e5. doi: 10.1016/j.chembiol.2019.06.001. Epub 2019 Jun 27. PMID: 31257183; PMCID: PMC6754270.
3: Yang J, Zhang Y, Cai Z, Zou J, Li S, Miao G, Lin H, Zhao X, Tan M. Inhibition of spastin impairs motor function recovery after spinal cord injury. Brain Res Bull. 2023 Dec;205:110806. doi: 10.1016/j.brainresbull.2023.110806. Epub 2023 Oct 31. PMID: 37918696.
4: Liu Q, Yang H, Luo J, Peng C, Wang K, Zhang G, Lin H, Ji Z. 14-3-3 protein augments the protein stability of phosphorylated spastin and promotes the recovery of spinal cord injury through its agonist intervention. Elife. 2024 Jan 17;12:RP90184. doi: 10.7554/eLife.90184. PMID: 38231910; PMCID: PMC10945579.
